Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

"Beyond the Scale" launches across Singapore with a clear and urgent call to focus on obesity as not a failure of willpower, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk (NVO) closed at $69.82 in the latest trading session, marking a +1.16% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.11%. At the same time, the Dow added 0.91% ...

Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Beyond the Scale” focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based care.SINGAPORE - Media OutReach Newswire - 27 June 2025 ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...